Aktuellt
SENASTE
Redeye argues that the ISOCOMFORT study results do not raise any concerns for its market outlook, and we reiterate our SEK88 base case. At large, the top-line results (for the entire patient population) strengthen our thesis of Sedana Medical’s trajectory, and we say that the per-protocol analysis (excluding non-protocol patients) should not be considered a significant question mark.
LÄS MER
